Randomized study comparing Baloxavir Marboxil to Peramivir in pediatric patients with Influenza

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1051180014

Enrollment

Registered

2018-12-17

Start date

2018-12-12

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza Influenza

Interventions

Interventions 1 Baloxavir marboxil Interventions 2 Peramivir

D008511

Medicine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)axillary temperature more than 37.5 degree 2)a positive rapid antigen test for influenza virus 3)a symptom duraiton of no more than 36 hours 4)hospitalized patient 5)body weight more than 10kg

Exclusion criteria

Exclusion criteria: 1)patients who have suffered from bacterial infection or other viral infection within one week from the start of the study 2)patients who received recipes of Baloxavir marboxil, Oseltamivir, Zanavivir, Laninavir, Peramivir within 4 weeks from the start of the study

Design outcomes

Primary

Measure	Time frame
The time to alleviation of influenza symptoms The time to resolution of fever	—

Secondary

Measure	Time frame
The changes from baseline in infectious virus and viral RNA titers	—

Contacts

Public ContactKentaro Kato

Kitano Hospital, Tazuke Kofukai Medical Research Institute

kenkato100@gmail.com+81-6-6312-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026